Phase 2 Study of VX-950, Pegasys and Copegus in Hepatitis C

Completed · Phase 2

Conditions studied: Hepatitis C

In brief

To assess the safety of the combination of VX-950, Pegasys and Copegus in subjects with hepatitis C.

Key facts

Study ID

NCT00262483

Run by

Vertex Pharmaceuticals Incorporated

People needed

12

Starts

2005-12-01

Expected to finish

2006-04-01

Last updated by the study team

2007-12-21

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Infected with hepatitis C virus

You may not qualify if…

• Contraindications to peginterferon or ribavirin therapy.

Where it is running

• Call for information — San Antonio, Texas, United States
• Call for information — Santurce, Puerto Rico

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.